Cargando…

Curcumol Targeting PAX8 Inhibits Ovarian Cancer Cell Migration and Invasion and Increases Chemotherapy Sensitivity of Niraparib

OBJECTIVE: To investigate the effects of Curcumol on invasion, migration and epithelial-mesenchymal transformation of IGROV-1 and OVCAR-3 cells in ovarian cancer and its potential mechanism. Meanwhile, the effect of Curcumol on the antitumor activity of Niraparib was analyzed. METHODS: Cell Counting...

Descripción completa

Detalles Bibliográficos
Autor principal:	Liu, Caihong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085303/ https://www.ncbi.nlm.nih.gov/pubmed/35548853 http://dx.doi.org/10.1155/2022/3941630

Ejemplares similares

Oleanolic Acid (OA) Targeting UNC5B Inhibits Proliferation and EMT of Ovarian Cancer Cell and Increases Chemotherapy Sensitivity of Niraparib
por: Zeng, Zhen, et al.
Publicado: (2022)

Niraparib for ovarian cancer
Publicado: (2021)

Rucaparib and Niraparib in Advanced Ovarian Cancer
por: Redelico, Tyler
Publicado: (2019)

MiR-326 inhibits trophoblast growth, migration, and invasion by targeting PAX8 via Hippo pathway
por: Zang, Junjie, et al.
Publicado: (2022)

Curcumol increases the sensitivity of colon cancer to 5-FU by regulating Wnt/β-catenin signaling
por: Gao, Jinfeng, et al.
Publicado: (2021)

Niraparib in ovarian cancer: results to date and clinical potential
por: Caruso, Davide, et al.
Publicado: (2017)

Niraparib-induced STAT3 inhibition increases its antitumor effects
por: Zhao, Qianqian, et al.
Publicado: (2022)

PAX8: a sensitive and specific marker to identify cancer cells of ovarian origin for patients prior to neoadjuvant chemotherapy
por: Wang, Yue, et al.
Publicado: (2013)

Curcumol inhibits encephalomyocarditis virus by promoting IFN-β secretion
por: Zheng, Jiangang, et al.
Publicado: (2021)

Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer
por: Zhong, Lixian, et al.
Publicado: (2018)

UnPAXing the Divergent Roles of PAX2 and PAX8 in High-Grade Serous Ovarian Cancer
por: Hardy, Laura R., et al.
Publicado: (2018)

Safety and management of niraparib monotherapy in ovarian cancer clinical trials
por: Monk, Bradley J, et al.
Publicado: (2023)

The PAX8 cistrome in epithelial ovarian cancer
por: Adler, Emily K., et al.
Publicado: (2017)

PAX2, PAX8, and PR are correlated with ovarian seromucinous borderline tumor with endometriosis
por: Yun, Bo Seong, et al.
Publicado: (2022)

To reveal pharmacological targets and molecular mechanisms of curcumol against interstitial cystitis
por: Wu, Ka, et al.
Publicado: (2019)

Therapeutic targets and functions of curcumol against COVID-19 and colon adenocarcinoma
por: Li, Jun, et al.
Publicado: (2022)

How to start niraparib in real-world Asian ovarian cancer patients?
por: Hong, Sook-Hee
Publicado: (2021)

Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma
por: Zhang, Jie Qing, et al.
Publicado: (2021)

Pharmacological effects of Niraparib and its combination with angiogenic inhibitor in ovarian cancer
por: Liu, Huiwen, et al.
Publicado: (2023)

Curcumol: From Plant Roots to Cancer Roots
por: Wei, Wei, et al.
Publicado: (2019)

Curcumol inhibits EMCV replication by activating CH25H and inhibiting the formation of ROs
por: Zheng, Jiangang, et al.
Publicado: (2022)

Cost-effectiveness of maintenance niraparib with an individualized starting dosage in patients with platinum-sensitive recurrent ovarian cancer in China
por: Shi, Yin, et al.
Publicado: (2023)

Curcumol Attenuates Endometriosis by Inhibiting the JAK2/STAT3 Signaling Pathway
por: Wang, Yan, et al.
Publicado: (2022)

PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation
por: Jonuscheit, Stephanie, et al.
Publicado: (2021)

Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
por: Lee, Arnold
Publicado: (2021)

Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting
por: Maiorano, Mauro Francesco Pio, et al.
Publicado: (2023)

Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer
por: O’Brien, Shane, et al.
Publicado: (2023)

Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer
por: Takehara, Kazuhiro, et al.
Publicado: (2021)

PAX8 and MECOM are interaction partners driving ovarian cancer
por: Bleu, Melusine, et al.
Publicado: (2021)

Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci
por: Kar, Siddhartha P, et al.
Publicado: (2017)

PAX8 as a Potential Target for Ovarian Cancer: What We Know so Far
por: Di Palma, Tina, et al.
Publicado: (2022)

MicroRNA-375 targets PAX6 and inhibits the viability, migration and invasion of human breast cancer MCF-7 cells
por: Zou, Qiongyan, et al.
Publicado: (2021)

An In-Depth Review of Niraparib in Ovarian Cancer: Mechanism of Action, Clinical Efficacy and Future Directions
por: Akay, Melek, et al.
Publicado: (2021)

Correction to: Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
por: Lee, Arnold
Publicado: (2021)

Curcumol inhibits the viability and invasion of colorectal cancer cells via miR-30a-5p and Hippo signaling pathway
por: Yu, Dan, et al.
Publicado: (2021)

Curcumol Inhibits the Development of Prostate Cancer by miR-125a/STAT3 Axis
por: Sheng, Wen, et al.
Publicado: (2022)

Curcumol Synergizes with Cisplatin in Osteosarcoma by Inhibiting M2-like Polarization of Tumor-Associated Macrophages
por: Wang, Jincheng, et al.
Publicado: (2022)

A role for PAX8 in the tumorigenic phenotype of ovarian cancer cells
por: Di Palma, Tina, et al.
Publicado: (2014)

Matrine suppresses the migration and invasion of NSCLC cells by inhibiting PAX2-induced epithelial-mesenchymal transition
por: Yang, Jun, et al.
Publicado: (2017)

The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China
por: Ni, Jing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9dk7dmlaudp8p327el3pp625tk